The use of post‐translationally modified peptides for detection of biomarkers of immune‐mediated diseases
- 27 August 2009
- journal article
- review article
- Published by Wiley in Journal of Peptide Science
- Vol. 15 (10), 621-628
- https://doi.org/10.1002/psc.1166
Abstract
Biomarkers are decision‐making tools at the basis of clinical diagnostics and essential for guiding therapeutic treatments. In this context, autoimmune diseases represent a class of disorders that need early diagnosis and steady monitoring. These diseases are usually associated with humoral or cell‐mediated immune reactions against one or more of the body's own constituents. Autoantibodies fluctuating in biological fluids can be used as disease biomarkers and they can be, thus, detected by diagnostic immunoassays using native autoantigens. However, it is now accepted that post‐translational modifications may affect the immunogenicity of self‐protein antigens, triggering an autoimmune response and creating neo‐antigens. In this case, post‐translationally modified peptides represent a more valuable tool with respect to isolated or recombinant proteins. In fact, synthetic peptides can be specifically modified to mimic neo‐antigens and to selectively detect autoantibodies as disease biomarkers. A ‘chemical reverse approach’ to select synthetic peptides, bearing specific post‐translational modifications, able to fishing out autoantibodies from patients' biological fluids, can be successfully applied for the development of specific in vitro diagnostic/prognostic assays of autoimmune diseases. Herein, we report the successful application of this approach to the identification of biomarkers in different autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. Copyright © 2009 European Peptide Society and John Wiley & Sons, Ltd.Keywords
This publication has 36 references indexed in Scilit:
- Designed Glycopeptides with Different β-Turn Types as Synthetic Probes for the Detection of Autoantibodies as Biomarkers of Multiple SclerosisJournal of Medicinal Chemistry, 2008
- In biomarkers we trust?Nature Biotechnology, 2005
- Reactivities to the Sm Autoantigenic Complex and the Synthetic SmD1-aa83–119 Peptide in Systemic Lupus Erythematosus and other Autoimmune DiseasesJournal of Autoimmunity, 2001
- The C-terminal RG Dipeptide Repeats of the Spliceosomal Sm Proteins D1 and D3 Contain Symmetrical Dimethylarginines, Which Form a Major B-cell Epitope for Anti-Sm AutoantibodiesPublished by Elsevier BV ,2000
- Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.JCI Insight, 1998
- Role of β-turn residues in β-hairpin formation and stability in designed peptidesJournal of Molecular Biology, 1997
- The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis.JCI Insight, 1993
- Recognition of synthetic peptides of Sm-D autoantigen by lupus seraClinical and Experimental Immunology, 1990
- Anti-keratin antibodies in rheumatoid arthritis.BMJ, 1979
- New Serum Factor in Patients with Rheumatoid Arthritis: The Antiperinuclear FactorAnnals Of The Rheumatic Diseases, 1964